This expansion follows the groundbreaking of a large-scale commercial drug product facility in Stein (CH), in another milestone for Lonza’s Drug Product Services (DPS) offering
The investment enhances Lonza’s capabilities and flexibility to support both clinical and commercial supply and will play a key role in meeting the growing market demand for bioconjugates
Through the new agreements, Cristal Therapeutics and McSAF will gain access to Lonza’s integrated bioconjugates offering and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates
Through the collaboration, Lonza will gain access to Singzyme’s enzymatic conjugation platform enabling the site-specific binding of payloads with peptidic linkers to proteins of interest
Data published in the prestigious journal ACS Central Science of the American Chemical Society
Subscribe To Our Newsletter & Stay Updated
